This trial is testing a new combination therapy for NASH and comparing it to placebo. The trial is double-blind, meaning neither the patients nor the researchers will know who is receiving the active drug or the placebo.
2 Primary · 8 Secondary · Reporting Duration: 48 weeks
380 Total Participants · 4 Treatment Groups
Primary Treatment: Tropifexor · Has Placebo Group · Phase 2
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: